Lorlatinib (Lorbrena): CADTH Reimbursement Recommendation [Internet]
- PMID: 38232201
- Bookshelf ID: NBK599021
Lorlatinib (Lorbrena): CADTH Reimbursement Recommendation [Internet]
Excerpt
What Is the CADTH Reimbursement Recommendation for Lorbrena?: CADTH recommends that Lorbrena should be reimbursed by public drug plans for the treatment of adult patients with ALK-positive locally advanced or metastatic non–small cell lung cancer (NSCLC) if certain conditions are met.
Which Patients Are Eligible for Coverage?: Lorbrena should only be covered to treat adult patients with ALK-positive NSCLC who are diagnosed when their cancer has spread to lymph nodes (locally advanced disease) or other parts of the body (metastatic disease) and who have had no prior systemic treatment for advanced or metastatic NSCLC.
What Are the Conditions for Reimbursement?: Lorbrena should only be reimbursed by public drug plans when used as a single drug. It should be prescribed by an oncologist with experience in the treatment of ALK-positive NSCLC although thereafter it can be given in an outpatient clinic by the patient’s health care team. The cost of Lorbrena should not be higher than the cost of treatment with alectinib or brigatinib for these patients.
Why Did CADTH Make This Recommendation?:
Evidence from a clinical trial demonstrated that Lorbrena delayed disease progression when compared with crizotinib in patients with metastatic ALK-positive NSCLC. Evidence suggested that Lorbrena was effective in treating and preventing brain metastases in patients with ALK-positive NSCLC.
Lorbrena meets patient needs of improving disease control by delaying progression and having manageable side effects.
Based on CADTH’s assessment of the health economic evidence, Lorbrena does not represent good value to the health care system at the public list price. The committee determined that there is not enough evidence to justify a higher price for Lorbrena than alectinib and brigatinib.
Based on public list prices, Lorbrena is estimated to cost the public drug plans approximately $8 million over the next 3 years; however, the actual budget impact is uncertain.
What Is Metastatic : ALK-positive NSCLC is a subtype of lung cancer that is caused by a mutation in the ALK gene, which accounts for approximately 5% of NSCLC cases. Patients with an ALK gene mutation tend to have a poor life expectancy and a high chance of developing brain metastases.
Unmet Needs in Metastatic : Treatments that improve the survival of patients, are less toxic, and are better at treating brain metastases are needed.
How Much Does Lorbrena Cost?: The sponsor estimated that treatment with Lorbrena would cost approximately $8,982 per 28-day cycle.
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.
Similar articles
-
Cemiplimab (Libtayo): CADTH Reimbursement Recommendation: Indication: First-line treatment of adult patients with non–small cell lung cancer (NSCLC) expressing PD-L1 (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK, or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jun. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jun. PMID: 38748829 Free Books & Documents. Review.
-
Pralsetinib (Gavreto): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with rearranged during transfection (RET) fusion–positive locally advanced unresectable or metastatic non–small cell lung cancer (NSCLC) [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct. PMID: 38620394 Free Books & Documents. Review.
-
Sacituzumab Govitecan (Trodelvy): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb. Report No.: PC0323. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb. Report No.: PC0323. PMID: 38588346 Free Books & Documents. Review.
-
Amivantamab (Rybrevant): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar. Report No.: PC0289. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar. Report No.: PC0289. PMID: 37883613 Free Books & Documents. Review.
-
Trastuzumab Deruxtecan (Enhertu): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH–) breast cancer who have received at least 1 prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive breast cancer should have received at least 1 and be no longer considered for endocrine therapy [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jul. Report No.: PC0305. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jul. Report No.: PC0305. PMID: 37782730 Free Books & Documents. Review.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous